Ieramilimab is under clinical development by Novartis and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Ieramilimab’s likelihood of approval (LoA) and phase transition for Metastatic Melanoma took place on 22 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ieramilimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Ieramilimab overview

Ieramilimab (LAG-525) is under development for the treatment of solid tumors including advanced triple-negative breast cancer, metastatic melanoma, mesothelioma, non-small cell lung cancer, renal cancer, small cell lung cancer and hematologic malignancies including diffuse large B-cell lymphoma and colorectal cancer. It is administered intravenously. The drug candidate is a humanized version of IMP701 antibody and acts by targeting the lymphocyte activation gene 3 protein (LAG3).

It was also under development for treatment of gastro-esophageal adenocarcinoma, castration-resistant prostate adenocarcinoma, soft tissue sarcoma, advanced neuroendocrine tumors and ovarian adenocarcinoma.

Novartis overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Quick View Ieramilimab LOA Data

Report Segments
  • Innovator
Drug Name
  • Ieramilimab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Novartis
  • Originator: Immutep
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.